Sinomenine treats Rheumatoid Arthritis by regulating IL-6 Gene Promoter Methylation.

Area of Science:

• Pharmacology and Immunology
• Epigenetics
• Traditional Chinese Medicine

Background:

• Sinomenine (SIN), derived from Sinomenium acutum, shows therapeutic potential for rheumatoid arthritis (RA).
• The precise molecular mechanisms underlying SIN's anti-RA effects are not fully elucidated.
• Understanding SIN's mechanism is crucial for optimizing its use in RA treatment.

Purpose of the Study:

• To investigate the anti-inflammatory and anti-RA mechanisms of SIN.
• To explore SIN's effect on interleukin-6 (IL-6) gene promoter methylation.
• To integrate network pharmacology and experimental validation for mechanism discovery.

Main Methods:

• Network pharmacology and bioinformatics identified key targets and pathways of SIN in RA.
• Molecular docking assessed SIN's binding affinity to identified targets.
• In vitro studies used LPS-stimulated cells to evaluate inflammatory markers and IL-6 promoter methylation.
• In vivo studies utilized a collagen-induced arthritis (CIA) rat model to assess therapeutic efficacy.

Main Results:

• SIN primarily targets TNF-α, IL-1β, IL-6, STAT3, PTGS2, and JAK2, mainly through the JAK-STAT pathway.
• In vitro, SIN inhibited LPS-induced inflammation and increased IL-6 promoter methylation.
• In vivo, SIN treatment reduced paw edema, arthritis severity, and inflammatory cytokine levels in CIA rats.

Conclusions:

• Sinomenine alleviates RA progression and inflammation through epigenetic modification of the IL-6 gene promoter.
• Enhanced IL-6 promoter methylation by SIN is a key mechanism in modulating inflammatory responses.
• This study highlights the potential of SIN as an epigenetic therapeutic agent for RA.